Where did our name come from?

We’re called Q’Apel for the Qu’Appelle River, a waterway that winds through Saskatchewan, Canada. Why? Because this pristine river charts a winding path, full of twists, turns, and straightaways alike. That’s what we do, too. Our cutting-edge products—neurological catheters, specifically—are designed to navigate the twists and turns of the brain’s neurovasculature, empowering therapeutic thrombectomy and cerebral aneurysm devices to deliver life-changing outcomes.

Who We Are
View All Resources

Randomized assessment of rapid endovascular treatment of ischemic stroke.

February 11, 2015

Abstract, via The New England Journal of Medicine:

Among patients with a proximal vessel occlusion in the anterior circulation, 60 to 80% of patients die within 90 days after stroke onset or do not regain functional independence despite alteplase treatment.

We evaluated rapid endovascular treatment in addition to standard care in patients with acute ischemic stroke with a small infarct core, a proximal intracranial arterial occlusion, and moderate-to-good collateral circulation.

Publication Link:
https://pubmed.ncbi.nlm.nih.gov/

Related readings.

Our utmost commitment: creating what works based specifically and urgently on what’s needed. Explore additional resources, publications, and webinars to learn more.

August 23, 2021

Q’Apel Medical Launches Armadillo – A New Radial Artery Access Platform to Meet the Needs of Physicians and Patients

August 9, 2021

Q’Apel Medical Welcomes Thomas Berryman, Chief Financial Officer

July 27, 2021

Q’Apel Medical Announces Move to New Headquarters Facility in Fremont, CA

May 17, 2021

Q’Apel Medical Welcomes Jodie Fam, Vice President and General Manager, International